DDC Conf. April 15 San Deigo, CA. Talk: Advancing Obesity Drug Discovery with Qualified Cell-based Assays for GLP-1 & Beyond

Obesity, a global chronic disease, has seen breakthroughs with GLP-1 and GIP therapeutics, sparking interest in next-generation drugs targeting additional receptors like glucagon, amylin, NPY2R, apelin, and others. This presentation highlights challenges and opportunities in obesity drug discovery, leveraging well-characterized assay solutions used to accelerate 100+ programs globally. We will explore pre-qualified functional assays — measuring cAMP, β-arrestin, and receptor internalization — for effective screening, characterization, and commercial development of obesity-related therapeutics.